Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)

Factor XII (FXII) is a serine protease involved in multiple cascades, including the kallikrein–kinin system. It may play a role in diseases in which the downstream cascades are dysregulated, such as hereditary angioedema. Garadacimab (CSL312) is a first‐in‐class, fully human, monoclonal antibody tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawaskar, Dipti, Chen, Xi, Glassman, Fiona, May, Frauke, Roberts, Anthony, Biondo, Mark, McKenzie, Andrew, Nolte, Marc W., Jusko, William J., Tortorici, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932701/
https://www.ncbi.nlm.nih.gov/pubmed/34811931
http://dx.doi.org/10.1111/cts.13192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932701/
https://www.ncbi.nlm.nih.gov/pubmed/34811931
http://dx.doi.org/10.1111/cts.13192

Ejemplares similares